Amplifica Holdings Group, Inc., a US-based, privately held, clinical-stage biopharmaceutical company, announced on Thursday that it has entered into an exclusive license agreement with The Regents of the University of California for a proprietary pipeline product that expands upon research in hair biology.

Frank Fazio, president and CEO, said, 'Amplifica is focused on identifying and developing solutions for androgenic alopecia and this expanded agreement with the University of California is another example of the company's pursuit to combat hair loss.'

Development Cell, a peer-reviewed scientific journal of cell and developmental biology recently published early- stage results for SCUBE3, a multifunctional signalling protein. The data showcased that SCUBE3 helps growth of normal hair follicles and can potentially stimulate new hair growth when implemented to skin. SCUBE3 will now be referenced as AMP-601 and is presently undergoing pre-clinical testing at Amplifica.